Clinical trial
A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
To compare progression-free survival in patients with HER1- and/or HER2-overexpressing stage IV bladder cancer who have been randomized to maintenance therapy with lapatinib ditosylate or placebo following first-line chemotherapy.
| Category | Value |
|---|---|
| Study start date | 2012-11-20 |